PPARG and chronic obstructive pulmonary disease: However, no significant association was found between the expression of PPARG, GLP-1R, and SLC5A2 and outcome phenotypes through SMR analysis, while KCNJ11 and DPP4 inhibitors may reduce the risk of COPD.